Skip to main content
Premium Trial:

Request an Annual Quote

Pyrosequencing Adds to Chemistry Product Line with $35M Biotage Acquisition

NEW YORK, Oct. 14 (GenomeWeb News) - Pyrosequencing said today that it has entered into an agreement with Dyax to acquire Biotage, a wholly owned subsidiary of Dyax that specializes in small-molecule purification and separation systems, for approximately $35 million in cash.

Pyrosequencing, which expanded its product line to include medicinal chemistry following its recent acquisition of Personal Chemistry, said the Biotage acquisition would enhance its chemistry portfolio.

Pyrosequencing said it plans to take over the mortgage on Biotage's newly built premises in Virginia, which will reduce the purchase price to approximately $30 million.

Biotage reported net sales of $23.2 million in 2002. The company has 126 employees.


The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.